Insight Molecular Diagnostics files offering as FDA review of GraftAssureDx continues
The Nasdaq Capital Market company filed a preliminary prospectus supplement for a stock and pre-funded warrant offering while its De Novo request for a transplant rejection test remains under FDA review.
Insight Molecular Diagnostics Inc., trading on Nasdaq as "IMDX," filed a preliminary prospectus supplement dated November 16, 2026 for an offering of common stock and pre-funded warrants. The company has engaged Lake Street Capital Markets, LLC as sole underwriter on a firm commitment basis.1 On November 13, 2026, the last reported closing price of the company's common stock on Nasdaq was $2.14 per share.1 Certain of the company's directors and officers indicated interest in purchasing shares of common stock in the offering at the public offering price.1
The filing details ongoing FDA interaction over the company's lead product, GraftAssureDx, a kitted in vitro diagnostic test for transplanted organ rejection. On March 25, 2026, the company submitted a De Novo request, including a data package, to the FDA seeking marketing authorization for GraftAssureDx.1 On July 25, 2026 the company received an Additional Information letter from the FDA identifying deficiencies in the De Novo request, relating primarily to the design and analysis of the clinical validation study, along with analytical, software and third-party component matters.1 FDA's preliminary view is that the clinical data submitted do not yet support the proposed intended use.1
Because FDA automatically places De Novo requests on hold upon issuance of such a letter, with 180 days to respond, the company's complete response is due by January 21, 2027.1 If FDA does not receive a complete response by that date, it will consider the De Novo request withdrawn, requiring a new submission.1 The company met with FDA on September 29, 2026 to discuss its response approach, and received written FDA feedback on October 30, 2026.1 Net proceeds from the offering are intended for general working capital and corporate purposes, including research and development in the transplantation category.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.